AtriCure (ATRC) announced that the first patient was enrolled and treated in the BoxX-NoAF clinical trial. The first patient was treated at Orlando Health Heart and Vascular Institute in Orlando, Florida.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATRC:
- AtriCure’s Ongoing Study: Implications for Cardiac Treatment and Market Performance
- AtriCure’s Cryoablation Study: A New Frontier in Pain Management
- AtriCure’s TRAC-AF Registry: A Closer Look at Ongoing Clinical Study
- AtriCure’s BoxX-NoAF Trial: A Step Forward in Cardiac Surgery Innovation
- AtriCure’s HEAL-IST IDE Trial: A Promising Step in Treating Inappropriate Sinus Tachycardia